|Bid||1.05 x 26500|
|Ask||1.10 x 13800|
|Day's Range||1.10 - 1.15|
|52 Week Range||1.05 - 3.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 19, 2018 - Feb 20, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.50|
MARLBOROUGH, Mass. and BERLIN, Feb. 1, 2018 /PRNewswire/ -- GKV-Spitzenverband, the head office of German statutory health insurance (SHI), confirmed their decision to list the ReWalk (RWLK) Personal 6.0 Exoskeleton System in the German Medical Device Directory (MDD, Hilfsmittelverzeichnis), according to §139 SGB V. The MDD is a comprehensive list of all medical devices which are principally and regularly reimbursed by German SHI providers. This decision means that ReWalk will be listed among all medical devices for compensation, which SHI providers can procure for any approved beneficiary on a case-by-case basis.
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Jan. 05, 2018-- ReWalk Robotics Ltd. today announced the Company has appointed its Corporate Controller, Ori Gon as Chief Financial Officer, effective February ...
While small-cap stocks, such as ReWalk Robotics Ltd (NASDAQ:RWLK) with its market cap of $32.95M, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...
When ReWalk Robotics Ltd (NASDAQ:RWLK) released its most recent earnings update (30 September 2017), I wanted to understand how these figures stacked up against its past performance. The two benchmarksRead More...
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Nov. 30, 2017 /PRNewswire/ -- ReWalk Robotics' (RWLK) ("ReWalk" or the "Company") innovative Restore soft exoskeleton system was featured in a recent story as one of the cutting edge technologies seeking to help stroke survivors heal and retain critical motor skills. The story published in Medical Device & Diagnostic Industry (MD&DI), a leading industry trade magazine. Priced at $19,500, the soft exosuit is anticipated to begin commercialization in late 2018 or early 2019.
While many momentum-focused investors focus on buying stocks near new highs and hoping the upward trend continues, other investors find value in searching for stocks that are poised to rebound after hitting new lows. Check out these slumping stocks that could be poised for a rebound soon.
YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., Nov. 28, 2017-- ReWalk Robotics Ltd. today announced that National Securities Corporation, the underwriter of ReWalk’ s underwritten public offering of ordinary ...
Zacks.com highlights: Drive Shack, Cerus, ReWalk Robotics, Aerohive Networks and Cloud Peak Energy
Categories: Yahoo FinanceGet free summary analysis ReWalk Robotics Ltd. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of ReWalk Robotics Ltd. – Natus Medical Incorporated (BABY-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 1.73 million, Net Earnings of USD -5.85 ... Read more (Read more...)
The Yokneam Ilit, Israel-based company said it had a loss of 27 cents per share. Losses, adjusted for non-recurring costs, were 22 cents per share. The maker of wearable robotic exoskeletons that help ...
NEW YORK, NY / ACCESSWIRE / November 2, 2017 / ReWalk Robotics Ltd. (NASDAQ: RWLK ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 2, 2017 at 8:30 AM Eastern ...
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Nov. 2, 2017 /PRNewswire/ -- ReWalk Robotics Ltd. ("ReWalk" or the "Company") (RWLK) today announced that Germany's national social accident insurance provider, Deutsche Gesetzliche Unfallversicherung ("DGUV"), approved the rental of the 20th ReWalk Personal exoskeleton system for qualifying beneficiaries. Additionally, DGUV recently signed a confirmation letter stipulating that DGUV's member payers, including the health insurance association Berufsgenossenschaft (also known as BG) and state insurers, will approve the supply of exoskeleton systems for qualifying beneficiaries on a case-by-case basis. The growing number of system rentals, along with the recent coverage confirmation from DGUV, reflects broader adoption of the procurement process by DGUV member payers across Germany.
Exo-suits that raise productivity and reduce work-related injuries are less complex and face fewer regulatory hurdles than robotic suits designed for victims of spinal injury or stroke. Advances in suits for industry "will speed the development of low cost, more functional rehabilitation/enable systems," said Dan Kara, research director at technology market intelligence firm ABI Research. ABI projects that robotic exoskeleton sales will jump from $97 million globally in 2016 to $1.9 billion by 2025.
YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., Oct. 16, 2017 /PRNewswire/ -- ReWalk Robotics Ltd. (RWLK) ("ReWalk") today announced that the soft exosuit technology currently in development has entered the next phase of testing and verification in collaboration with researchers at Harvard University's Wyss Institute for Biologically Inspired Engineering. This phase of testing includes evaluating the ReWalk exosuit system that is based on Wyss Institute exosuit technology with individuals who have had a stroke, in preparation for upcoming clinical trials to be run at clinical sites in 2018. This technology is designed for use by stroke survivors with lower limb disability. Soft exoskeleton technology, also called a soft exosuit, is being designed to serve a number of patient populations, including individuals with Multiple Sclerosis, Parkinson's Disease and other mobility challenges.
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Oct. 16, 2017 /PRNewswire/ -- ReWalk Robotics Ltd. (RWLK) ("ReWalk") announced today completion of all internal processes to initiate clinical studies and the initial production of its "soft suit" exoskeleton design for stroke patients. Called "Restore," the new system is the first product in the company's expansion into new technologies that will serve mobility-challenged patient communities. This design is targeted to serve the stroke rehabilitation community. "Achieving successful laboratory testing and design review processes with the Restore system is a milestone that advances our efforts for commercialization," said ReWalk CEO Larry Jasinski. "The potential of these soft suit designs to expand the utilization of robotic technologies initially with stroke patients in rehab—and in the future for community use—is meaningful.
As the USD $32.62M market cap ReWalk Robotics Ltd (NASDAQ:RWLK) released another year of negative earnings, investors may be on edge waiting for breakeven. The single most important question toRead More...
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Sept. 14, 2017 /PRNewswire/ -- ReWalk Robotics Ltd. ("ReWalk" or the "Company") (RWLK), today announced that one of the leading German insurers, Barmer, has signed a confirmation regarding the provision of ReWalk systems for all qualifying beneficiaries. "The continued expansion of data, the growing number of successful ReWalk users worldwide and the positive decision from the German Social Court have led Barmer to determine that exoskeletons are a standard of care for use in everyday life," said ReWalk CEO Larry Jasinski. Barmer has already begun processing claims with three beneficiaries entering training for in-home use of an exoskeleton.
Categories: Yahoo FinanceGet free summary analysis ReWalk Robotics Ltd. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of ReWalk Robotics Ltd. – Natus Medical Incorporated and Hologic, Inc. (BABY-US and HOLX-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 2.01 million, ... Read more (Read more...)